Wu, Yuan-Kun AdenYuan-Kun AdenWuYu, An-LiAn-LiYuMEI-FANG CHENGLin, Lung-ChunLung-ChunLinMING-JEN LEEChou, Chia-HungChia-HungChouHSUEH-WEN HSUEHCHIA-TUNG SHUNPING-HUEI TSENGLin, Siao-PingSiao-PingLinJYH-MING JIMMY JUANGCHI-CHAO CHAOMAO-YUAN SUSUNG-TSANG HSIEHCHENG-HSUAN TSAIYEN-HUNG LIN2024-03-012024-03-0120242040-6223https://scholars.lib.ntu.edu.tw/handle/123456789/640045Transthyretin cardiomyopathy (ATTR-CM) is a debilitating disease that has received much attention since the emergence of novel treatments. The Transthyretin Cardiomyopathy Clinical Trial showed that tafamidis, a transthyretin tetramer stabilizer, effectively reduced the declines in functional capacity and quality of life. However, Ala97Ser (A97S) hereditary ATTR-CM is underrepresented in major ATTR-CM tafamidis trials.enA97S; cardiomyopathy; speckle tracking echocardiography; tafamidis; transthyretin[SDGs]SDG3journal article10.1177/20406223231222828382239052-s2.0-85182813034